- Home
- CLSK vs VRDN Comparison
CLSK vs VRDN Comparison
Compare CLSK & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLSK | VRDN |
|---|---|---|
| Founded | 1987 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CLSK | VRDN |
|---|---|---|
| Price | $12.43 | $31.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | $23.66 | ★ $41.17 |
| AVG Volume (30 Days) | ★ 24.0M | 1.5M |
| Earning Date | 02-05-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.12 | N/A |
| Revenue | ★ $766,314,000.00 | $70,789,000.00 |
| Revenue This Year | $17.65 | $26,257.62 |
| Revenue Next Year | $20.56 | $10.69 |
| P/E Ratio | $10.68 | ★ N/A |
| Revenue Growth | 102.21 | ★ 23340.07 |
| 52 Week Low | $6.45 | $9.90 |
| 52 Week High | $23.61 | $34.04 |
Technical Indicators
Market Signals| Indicator | CLSK | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 51.56 | 54.82 |
| Support Level | $11.55 | $29.63 |
| Resistance Level | $12.36 | $32.70 |
| Average True Range (ATR) | 0.73 | 1.10 |
| MACD | 0.20 | -0.09 |
| Stochastic Oscillator | 84.44 | 73.86 |
Price Performance
Historical ComparisonAbout CLSK CleanSpark Inc.
Cleanspark Inc. is a data center developer that, until recently, focused exclusively on bitcoin mining. The company provides scalable, energy-efficient digital infrastructure across the United States. The Company has a sole reporting segment, which is the bitcoin mining segment.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).